Australia markets close in 2 hours 4 minutes

BELLUS Health Inc. (BLU)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.790.00 (0.00%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close5.79
Open5.71
Bid5.60 x 1400
Ask5.79 x 1400
Day's range5.43 - 6.07
52-week range2.01 - 6.34
Volume2,068,245
Avg. volume1,808,201
Market cap453.574M
Beta (5Y monthly)-0.55
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough

    LAVAL, Quebec, September 13, 2021--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced positive findings from a preplanned administrative interim analysis of the ongoing Phase 2b SOOTHE trial of BLU-5937, the Company’s highly selective P2X3 antagonist, in patients with refractory chronic cou

  • Business Wire

    BELLUS Health to Present at the H.C. Wainwright Global Investment Conference

    LAVAL, Quebec, September 02, 2021--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company at the H.C. Wainwright Global Investment Conference.

  • Business Wire

    BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021

    LAVAL, Quebec, August 23, 2021--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today announced that an abstract covering additional data from the RELIEF Phase 2a trial has been accepted for oral presentation at the upcoming European Respiratory Society ("ERS") International Congress 2021, being